Telecoms and AI Infrastructure Earnings Preview: DY, CIEN and AVGO CMC Markets

One of the anonymous complainants says that Spacey assaulted him while the man was working as a driver. The other said that he had gone up to Stacey's flat after meeting him at the Old Vic, and that he didn't recall how he passed out or went to sleep, but woke up to find Spacey assaulting him.

She said it appeared Mrs Ford had begun to exhibit symptoms at the end of May, so there was nothing that could have been done at the hospital that would have saved her.

While Nvidia (NVDA) gets the lion’s share of investors’ attention for the popularity of its advanced semiconductor chips, it would be a huge mistake to overlook Broadcom (AVGO). The chipmaker is carving out its own space in the market with specialty products that are cheaper than Nvidia’s chips. With Broadcom’s earnings report coming up on March 4, what should investors expect from the chipmaker? About Broadcom Stock Based in San Jose, California, Broadcom is a leading semiconductor company whose products are used in data centers, telecommunication equipment, broadband, and more. The company has a market capitalization of nearly $1.5 trillion, ranking it in the top 10 in the world among publicly traded companies. Broadcom’s chips are in high demand as high-performance semiconductors are needed to design, train, and run artificial intelligence platforms. Broadcom’s answer to this need is its custom ASIC chips, or application-specific integrated circuits, designed to handle the specific workloads of its clients. That means that the chips are less flexible than Nvidia’s general-purpose graphics processing units. Still, it also makes Broadcom’s chips cheaper—an important consideration as companies are spending billions on AI infrastructure. Broadcom currently has a $10 billion deal to supply Anthropic with custom chips, and it’s working with Alphabet (GOOG) (GOOGL) to create that company’s Tensor Processing Units (TPUs) that Google is using as an alternative to Nvidia GPUs. AVGO stock is up 65% in the last 12 months, handily beating the performance of the S&P 500 ($SPX) (up 15%) and Nvidia (up 56%). However, Broadcom's stock comes at somewhat of a premium, with a forward price-to-earnings ratio of 30.4 versus Nvidia’s 21.8. The stock also pays a dividend yield of 0.8%—not huge, but a pleasant bonus for a tech stock. A Look at Broadcom’s Most Recent Earnings Broadcom had a solid earnings report for the fourth quarter of fiscal 2025 (ending Nov. 2). Revenue of $18 billion...

黄金暴跌超 5%，终结四日连涨行情。尽管中东冲突持续升级，但美元走强与债券收益率攀升，抵消了黄金作为避险资产的吸引力。 法国兴业 银行与 MKS PAMP SA 的大宗商品策略师表示，周二美股深度抛售，迫使部分投资者平掉贵金属仓位，以满足投资组合其他部分的保证金追缴要求。 此外，部分交易员担忧，能源价格飙升可能推 高通 胀，进而提升美联储更长时间维持利率不变的可能性。黄金虽历来被视为抗通胀工具，但高利率通常会压制无息黄金的吸引力，美元走强亦会产生同样效果。 本周以来，美元指数已上涨约 1.5%；周二，两年期美国国债收益率逼近年内高点。交易员目前预计，美联储今年降息幅度将超过 25 个基点，而就在上周五，市场还完全定价了两次降息。 德国商业银行外汇与大宗商品研究主管 Thu Lan Nguyen 在报告中写道：“2022 年俄乌冲突推高油价并引发全球通胀的经历，很可能成为当前市场的参照模板。” 她指出，当时美联储提前加息、美元走强，黄金全年随之走弱。 截至纽约时段，现货黄金跌至每盎司____美元；白银暴跌至每盎司____美元；铂金与钯金亦大幅下挫。 贵金属市场数月来波动剧烈，部分原因在于今年金价、银价屡创历史新高，日内剧烈震荡，已将部分交易商的风险敞口推至允许上限附近。 本周初，投资者涌入避险资产，金价一度上涨；周二，战争范围进一步扩大。特朗普总统表示，美国将持续军事打击直至目标达成；以色列宣布对伊朗指挥中心发动 “一波打击”。与此同时，伊朗袭击油气基础设施，并威胁霍尔木兹海峡这一战略航道的航运安全。 即便在周末美以袭击伊朗之前，美国通胀回升的迹象已显现。美国供应管理协会数据显示，2 月制造业投入价格以 2022 年以来最快速度飙升。 摩根大通 首席执行官杰米・戴蒙警告，通胀可能成为美国经济 “派对上的臭鼬”（即扫兴因素）。 今年以来，金价已上涨超 25%，持续的地缘政治与贸易紧张局势、以及对美联储独立性的担忧支撑了需求。投资者对通胀与货币贬值的担忧重燃，为这轮多年涨势注入新动力。 瑞士私人银行 UBP SA 在报告中称，若中东冲突持续数周，黄金 “有充足空间” 挑战 1 月底触及的每盎司 5595 美元以上的历史高点。周一，金价收于一个多月来的最高水平。 除扰乱能源供应外，战争还造成贵金属实物运输瓶颈。全球黄金贸易主要枢纽阿联酋周末关闭领空，多家商业航空公司暂停海湾...

Mazda ( MZDAY ) North American Operations (MNAO) reported on Tuesday total February sales of 33,497 vehicles, flat compared to February 2025. With 24 selling days in February, compared to 25 the year prior, the company posted an increase of 4 percent on a daily selling rate (DSR) basis. CPO sales totaled 5,954 vehicles in February, an increase of 6.4 percent compared to February 2025. Mazda Canada reported February sales of 4,616 vehicles, an increase of 1.3 percent compared to February last year. Mazda Motor de Mexico (MMdM) reported February sales of 8,321 vehicles, a decrease of 11 percent compared to February last year. Source: Press Release More on Mazda Motor Corporation Mazda: Lower Tariffs Than Expected Mean Inventory Push Seeking Alpha’s Quant Rating on Mazda Motor Corporation Historical earnings data for Mazda Motor Corporation Dividend scorecard for Mazda Motor Corporation Financial information for Mazda Motor Corporation

A new one-a-day-pill holds promise for HIV's 'forgotten population' toggle caption Science Source Is there one pill a day to keep me healthy? That's a question that Dr. Chloe Orkin hears a lot from her older HIV patients who take many medications each day to keep the virus under control. "They keep asking: 'Why can't I have a single pill? Or can I have injections?' And you have to keep saying: 'No,'" explains Orkin , who is a physician and a researcher at Queen Mary University of London. It's not a pipe dream. Most of the world's 40 million HIV patients can already take a single daily pill each day to keep the virus at bay or injections every two months. Sponsor Message But these treatment options don't work for many of Orkin's patients, especially the HIV patients who were diagnosed in the early days of the AIDS epidemic, in the '80s and '90s "while we were learning about how to treat HIV," says Orkin. "They had drugs that didn't work that well, and therefore they developed some resistance to these medications." Another group of HIV patients who've developed resistance are those who have not been able to take their HIV medications consistently. The result? These individuals must take many pills, multiple times a day, to keep the virus in check. Orkin says this is challenging logistically but also because some of the drugs have side effects — such as diarrhea — and some patients are taking medications for other conditions that can have problematic interactions with the HIV medications. For example, Orkin says, a type of HIV medication, called boosted protease inhibitors, can mean a person suffers worse side effects from the other non-HIV drugs. Tens of thousands of HIV patients in the U.S. are on these complex regimens and many more globally, although Orkin and others say it's hard to pin down an exact number. "Science has moved on for everyone else except for them," Orkin says. "They're like a forgotten population." Sponsor Message But soon, Orkin hopes to be able ...

伊朗局勢｜伊紅新月會推算境內787人死亡 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】美國和以色列持續攻擊伊朗，伊朗紅新月會推算境內死亡人數增至787人。 受襲的伊朗首都德黑蘭傳出多下爆炸聲，濃煙升上半空，以軍宣稱行動擊殺一名革命衛隊聖城旅指揮官。位於庫姆市一幢大樓亦中彈，嚴重損毀。伊朗媒體證實大樓原本用作舉行伊朗專家會議，推選接替已故最高領袖哈梅內伊，出事時沒有人在大樓內。 另外，美國駐迪拜大使館遇襲起火，據報是被伊朗無人機擊中，不過當時大使館已關閉，沒有人受傷。國務卿魯比奧指，大使館的停車場被擊中，大部分使館人員在出事前已撤離。

Source: Bloomberg, 0:00

Galaxy Digital ( GLXY:CA ) on Tuesday said that its board has approved the voluntary delisting of its Class A common stock from the Toronto Stock Exchange. The company said the delisting is expected to take effect at the close of markets on March 19, 2026. Its Class A common stock will continue to trade on the Nasdaq Stock Market under the symbol "GLXY." Galaxy said its previously announced normal course issuer bid through the TSX and alternative Canadian trading systems will terminate upon delisting, while repurchases on Nasdaq may continue in accordance with applicable securities laws. The company will remain a reporting issuer in Canada and continue to provide disclosure under Canadian securities laws. BRPHF is -5.10% to $20.62. Source: Press Release More on Galaxy Digital Holdings Ltd., Galaxy Digital Galaxy Digital Can't Escape The Crypto Mania (Rating Downgrade) Galaxy Digital: Buyer Beware! Galaxy Digital Inc. (GLXY) Q4 2025 Earnings AMA Call Transcript Galaxy Digital CEO: Bitcoin faces competition from sports betting, remains generational asset Galaxy Digital gets TSX approval for $200M share buyback

Pinterest’s new share-repurchase authorization represents nearly a third of the company’s market cap and signals to one analyst that an activist is satisfied with the company’s strategic vision.

格隆汇3月4日｜欧洲主要股指均大幅收跌，德国DAX30指数跌3.53%，英国富时100指数跌2.77%，法国CAC40指数跌3.46%，欧洲斯托克50指数跌3.61%，西班牙IBEX35指数跌4.67%，意大利富时MIB指数跌3.91%。

美联储周二发布的报告显示，去年，唐纳德・特朗普总统推行的大规模进口加税政策，叠加普遍通胀上行，给美国小企业带来了经营阻力。 作为 2025 年小企业信贷调查的一部分，美联储 12 家地区联储银行联合指出，2025 年这些小企业面临的 “最普遍挑战” 是商品、服务及劳动力成本的不断上涨。 超过四成受访企业表示，“关祱相关成本上升构成了财务压力”，其中零售与制造业企业感受最为强烈。在因总统加税政策面临成本上涨的企业中，76% 的受访者将部分成本转嫁给了下游，60% 的企业自行消化了部分开支。 报告称：“近半数企业表示，其至少部分生产投入品采购自美国境外，而这些企业中的绝大多数报告称，2024 至 2025 年间，海外投入品价格出现上涨。” 总体而言，企业并未因成本上升而更换供应商或将生产活动迁回美国境内。 特朗普的关祱体系是 2025 年通胀的重要推手，美联储官员将去年通胀率大幅超出 2% 目标的主要原因归咎于加税政策。多数美联储官员预计，今年关祱的影响将逐步消退。 特朗普政府多次宣称，关祱成本由外国承担，其目的既在于将产业迁回美国本土，也在于为政府创造财政收入。关祱也被反复用作胁迫性外交政策工具。 纽约联储与美国国会预算办公室近期发布的报告均发现，与总统对关祱的看法相反，关祱成本几乎完全由美国境内主体承担。最高法院裁定特朗普的大范围加税举措超出其权限，这一判决为关祱体系的前景蒙上阴影，尽管特朗普在该裁决后仍对进口商品加征了更多关祱。 美联储地区报告还调查了去年小企业对人工智能技术的应用情况，发现 AI 采用率不断上升，且几乎未造成就业市场岗位流失。 报告显示，近半数小企业正在使用 AI，另有 15% 的企业计划在未来一年内引入 AI 技术。美联储调查指出，目前 AI 的主要用途是文案撰写与营销，其次是提升个人工作效率。 报告称，AI 并未改变企业的劳动力成本，但确实提升了许多企业的生产效率。 责任编辑：郭明煜

财联社3月4日讯（编辑 史正丞） 北京时间周二晚间，苹果公司在第二波春季新品发布中更新MacBook条线，搭载M5芯片的MacBook Air，以及搭载全新M5 Pro/M5 Max芯片的MacBook Pro亮相。 从投资市场的角度来看，面对存储芯片全面涨价的压力，苹果采用了一种非常有趣的策略： 挥刀砍掉基础存储机型，使得起售价全面上涨变得不那么难以接受 。同时，机型整体定价水平抬高，有利于吸收存储涨价的压力。 苹果表示，M5版MacBook Air起步存储容量翻倍至512GB，并首次提供最高4TB的存储选项，同时新的固态硬盘读写性能较前代提升2倍。定价方面， 最基础的M5版MacBook Air定价为1099美元（国行8499元），比M4时期分别贵了100美元和500块人民币。 MacBook Pro的情况也类似。最低配的14英寸M5 Pro芯片电脑起售价为2199美元（国行17999元）， 较M4时代的机型贵了200美元和1000块人民币 ，但起步存储规格从512GB翻倍至1TB。 值得一提的是，苹果也在新闻稿尾部小字里宣布，去年秋季上市的M5版MacBook Pro将 只提供1TB起步的存储版本 。因此起步价也从512GB版本的12999元，提高至13499元。 苹果同时保持内存升级的价格不变。整体而言，将14英寸机型从24GB升级至48GB的费用为400美元。从48GB提升至64GB多花200美元，升级到128GB则多花1000美元。这些内存选项与更高端的CPU配置绑定，定价体系与M4 Pro系列完全相同。 与事前爆料一致，苹果的M5 Pro/M5 Max芯片也用上了台积电的SoIC-MH封装工艺，实现CPU和GPU解耦。在M1至M4时代，苹果的Pro和Max芯片本质上就是由两块和四块基础版芯片分别拼接而成。但M5时代，苹果采用了新的融合架构，将两块芯片晶粒组合成一个单片系统（SoC）。 其中，M5 Pro拥有最高18核CPU（6颗“超级核心”+12颗性能核心）和最高20核GPU，多线程能力较M4 Pro最高提升30%，在 处理AI任务时的峰值GPU算力性能较前代提高4倍 。 M5 Max与M5 Pro使用的是同一套架构，标配18核CPU和最多40核GPU，AI算力性能同样较前代提升超过4倍。新架构也意味着若想要入手高配GPU，唯一的选择就是M5 Max。

VAT Group AG press release ( VACNY ): FY GAAP EPS of CHF7.14. Revenue of CHF1.07B. More on VAT Group AG VAT Group AG 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on VAT Group AG Historical earnings data for VAT Group AG Dividend scorecard for VAT Group AG Financial information for VAT Group AG

谷歌公司推出Gemini 3.1 Flash-LITE模型。 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

In trading on Tuesday, shares of Taylor Morrison Home Corp (Symbol: TMHC) crossed below their 200 day moving average of $41.11, changing hands as low as $40.96 per share. Taylor Morrison Home Corp shares are currently trading down about 3.1% on the day. The chart below shows the one year performance of TMHC shares, versus its 200 day moving average: Looking at the chart above, TMHC's low point in its 52 week range is $23.51 per share, with $52.0861 as the 52 week high point — that compares with a last trade of $40.77. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

"There’s an argument that someone of our size and global reach should be larger, generally in private equity," Ares Management CEO Michael Arougheti says during a discussion with Bloomberg's Dani Burger at Bloomberg Invest. (Source: Bloomberg)

Investors eyeing a purchase of 10x Genomics Inc (Symbol: TXG) stock, but cautious about paying the going market price of $22.36/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $15 strike, which has a bid at the time of this writing of $1.45. Collecting that bid as the premium represents a 9.7% return against the $15 commitment, or a 20.6% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to TXG's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $15 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless 10x Genomics Inc sees its shares fall 32.1% and the contract is exercised (resulting in a cost basis of $13.55 per share before broker commissions, subtracting the $1.45 from $15), the only upside to the put seller is from collecting that premium for the 20.6% annualized rate of return. Below is a chart showing the trailing twelve month trading history for 10x Genomics Inc, and highlighting in green where the $15 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the August put at the $15 strike for the 20.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for 10x Genomics Inc (considering the last 251 trading day closing values as well as today's price of $22.36) to be 70%. For other put options contract ideas at the various different available expirations, visit the TX...

Investors considering a purchase of SailPoint Inc (Symbol: SAIL) shares, but tentative about paying the going market price of $14.02/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $10 strike, which has a bid at the time of this writing of $1.00. Collecting that bid as the premium represents a 10% return against the $10 commitment, or a 18.4% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to SAIL's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $10 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless SailPoint Inc sees its shares decline 28.5% and the contract is exercised (resulting in a cost basis of $9.00 per share before broker commissions, subtracting the $1.00 from $10), the only upside to the put seller is from collecting that premium for the 18.4% annualized rate of return. Below is a chart showing the trailing twelve month trading history for SailPoint Inc, and highlighting in green where the $10 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $10 strike for the 18.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for SailPoint Inc (considering the last 251 trading day closing values as well as today's price of $14.02) to be 56%. For other put options contract ideas at the various different available expirations, visit th...

Audible is rolling out a cheaper “Standard” subscription plan that costs $8.99 per month, the Amazon-owned company announced on Tuesday. The new plan is $6 cheaper than the platform’s existing “Premium” plan, which costs $14.95 per month. The Standard plan includes one audiobook per month from Audible’s catalog and unlimited listening from a curated library that includes a selection of Audible Originals. Under the new Standard plan, subscribers will lose access to the audiobooks they’ve consumed when they unsubscribe. The Premium plan lets users keep the audiobooks they’ve listened to even if they unsubscribe. The Standard plan also includes access to nearly 200 of the most popular titles available on the Wondery+ app, which is shutting down in the coming months. The Standard plan is launching in the United States, the United Kingdom, Canada, Australia, Germany, and France. Audible is testing the plan in additional markets, the company says. The launch of the new subscription plans comes as Audible is facing growing competition from Spotify, which launched audiobooks in 2022 and has bundled the format with music and podcasts as part of its own Premium subscription. Spotify said last October that the number of users listening to audiobooks rose 36% over the past year, and listening hours increased 37%. Additionally, it noted that more than half of Spotify’s 281 million premium subscribers have engaged with an audiobook. Techcrunch event Disrupt 2026: The tech ecosystem, all in one room Your next round. Your next hire. Your next breakout opportunity. Find it at TechCrunch Disrupt 2026, where 10,000+ founders, investors, and tech leaders gather for three days of 250+ tactical sessions, powerful introductions, and market-defining innovation. Register now to save up to $400. Save up to $300 or 30% to TechCrunch Founder Summit 1,000+ founders and investors come together at TechCrunch Founder Summit 2026 for a full day focused on growth, execution, and real-world scaling. ...

Audible is rolling out a cheaper “Standard” subscription plan that costs $8.99 per month, the Amazon-owned company announced on Tuesday. The new plan is $6 cheaper than the platform’s existing “Premium” plan, which costs $14.95 per month. The Standard plan includes one audiobook per month from Audible’s catalog and unlimited listening from a curated library that includes a selection of Audible Originals. Under the new Standard plan, subscribers will lose access to the audiobooks they’ve consumed when they unsubscribe. The Premium plan lets users keep the audiobooks they’ve listened to even if they unsubscribe. The Standard plan also includes access to nearly 200 of the most popular titles available on the Wondery+ app, which is shutting down in the coming months. The Standard plan is launching in the United States, the United Kingdom, Canada, Australia, Germany, and France. Audible is testing the plan in additional markets, the company says. The launch of the new subscription plans comes as Audible is facing growing competition from Spotify, which launched audiobooks in 2022 and has bundled the format with music and podcasts as part of its own Premium subscription. Spotify said last October that the number of users listening to audiobooks rose 36% over the past year, and listening hours increased 37%. Additionally, it noted that more than half of Spotify’s 281 million premium subscribers have engaged with an audiobook. Spotify recently hiked the price of its monthly subscription plan for the third time in three years, potentially opening the door to competitors like Audible. “By expanding our membership options, we’re maximizing access for lighter listeners while enabling publishers and creators to reach new audiences—a win-win that grows the entire audiobook category,” said Cynthia Chu, Chief Financial & Growth Officer at Audible, in a press release. Audible says early testing of the new plan showed strong member acquisition and retention rates, as testing in the U...

Investors eyeing a purchase of Kymera Therapeutics Inc (Symbol: KYMR) shares, but cautious about paying the going market price of $87.93/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $60 strike, which has a bid at the time of this writing of $7.20. Collecting that bid as the premium represents a 12% return against the $60 commitment, or a 15.1% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to KYMR's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $60 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Kymera Therapeutics Inc sees its shares decline 31.3% and the contract is exercised (resulting in a cost basis of $52.80 per share before broker commissions, subtracting the $7.20 from $60), the only upside to the put seller is from collecting that premium for the 15.1% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Kymera Therapeutics Inc, and highlighting in green where the $60 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the December put at the $60 strike for the 15.1% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Kymera Therapeutics Inc (considering the last 251 trading day closing values as well as today's price of $87.93) to be 74%. For other put options contract ideas at the various differen...

Investors considering a purchase of AnaptysBio Inc (Symbol: ANAB) stock, but cautious about paying the going market price of $53.97/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $35 strike, which has a bid at the time of this writing of $2.60. Collecting that bid as the premium represents a 7.4% return against the $35 commitment, or a 15.9% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to ANAB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $35 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless AnaptysBio Inc sees its shares fall 35.1% and the contract is exercised (resulting in a cost basis of $32.40 per share before broker commissions, subtracting the $2.60 from $35), the only upside to the put seller is from collecting that premium for the 15.9% annualized rate of return. Below is a chart showing the trailing twelve month trading history for AnaptysBio Inc, and highlighting in green where the $35 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the August put at the $35 strike for the 15.9% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for AnaptysBio Inc (considering the last 251 trading day closing values as well as today's price of $53.97) to be 64%. For other put options contract ideas at the various different available expirations, visit the ANA...

Investors eyeing a purchase of Olaplex Holdings Inc (Symbol: OLPX) shares, but cautious about paying the going market price of $1.52/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April put at the $1 strike, which has a bid at the time of this writing of 5 cents. Collecting that bid as the premium represents a 5% return against the $1 commitment, or a 40.6% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to OLPX's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $1 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Olaplex Holdings Inc sees its shares fall 33.8% and the contract is exercised (resulting in a cost basis of $0.95 per share before broker commissions, subtracting the 5 cents from $1), the only upside to the put seller is from collecting that premium for the 40.6% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Olaplex Holdings Inc, and highlighting in green where the $1 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the April put at the $1 strike for the 40.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Olaplex Holdings Inc (considering the last 251 trading day closing values as well as today's price of $1.52) to be 66%. For other put options contract ideas at the various different available expirations, vi...